These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Interferon: the quintessence of a quinquagenarian. De Clercq E Verh K Acad Geneeskd Belg; 2009; 71(1-2):5-14. PubMed ID: 19739395 [TBL] [Abstract][Full Text] [Related]
3. Early days in interferon research. Chany C Biochimie; 2007; 89(6-7):721-2. PubMed ID: 17573176 [TBL] [Abstract][Full Text] [Related]
4. Interferon, a growing cytokine family: 50 years of interferon research. Chelbi-Alix MK; Wietzerbin J Biochimie; 2007; 89(6-7):713-8. PubMed ID: 17544197 [TBL] [Abstract][Full Text] [Related]
5. Pharmacology and therapeutic potential of interferons. George PM; Badiger R; Alazawi W; Foster GR; Mitchell JA Pharmacol Ther; 2012 Jul; 135(1):44-53. PubMed ID: 22484806 [TBL] [Abstract][Full Text] [Related]
6. Interferons and their use in persistent viral infections. Chevaliez S; Pawlotsky JM Handb Exp Pharmacol; 2009; 189(189):203-41. PubMed ID: 19048202 [TBL] [Abstract][Full Text] [Related]
7. A brief history of the use of interferons as treatment of multiple sclerosis. Jacobs L; Johnson KP Arch Neurol; 1994 Dec; 51(12):1245-52. PubMed ID: 7986181 [TBL] [Abstract][Full Text] [Related]
8. A tribute to Jean Lindenmann, co-discoverer of interferon (1924-2015). Haller O Cytokine; 2015 Nov; 76(1):113-5. PubMed ID: 25937629 [TBL] [Abstract][Full Text] [Related]
9. [Multicenter study on the inhibition of hepatocarcinogenesis by interferon therapy (IHIT)]. Yoshida H; Omata M Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):463-6. PubMed ID: 15359842 [No Abstract] [Full Text] [Related]
10. [Human interferons: biological and clinical promises and premises]. Jasmin C Schweiz Med Wochenschr; 1991 Mar; 121(13):463-6. PubMed ID: 1709521 [TBL] [Abstract][Full Text] [Related]
11. Biologic effects of interferons: relevance to multiple sclerosis. Rudick RA; Ransohoff RM Mult Scler; 1995; 1 Suppl 1():S12-6. PubMed ID: 9345391 [TBL] [Abstract][Full Text] [Related]
12. Infectious Diseases Society of America. Trials of interferon therapy for multiple sclerosis. Abb J; Deinhardt F; Zander H; Tenser RB; Rapp F; Goust JM; Fudenberg HH; Vilcek J; Ho M; Merigan TC; Oldstone MB; Jackson GG J Infect Dis; 1982 Jul; 146(1):109-15. PubMed ID: 6177805 [No Abstract] [Full Text] [Related]
13. Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019? Maguire C; Frohman T; Zamvil SS; Frohman E; Melamed E Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32527763 [No Abstract] [Full Text] [Related]
15. Use of interferon in multiple sclerosis. McFarlin DE Ann Neurol; 1985 Oct; 18(4):432-3. PubMed ID: 2416264 [No Abstract] [Full Text] [Related]
16. Interferon: ten stories in one. A short review of some of the highlights in the history of an almost quinquagenarian. De Clercq E Acta Microbiol Immunol Hung; 2005; 52(3-4):273-89. PubMed ID: 16400870 [TBL] [Abstract][Full Text] [Related]
17. [Interferon in multiple sclerosis]. Cendrowski W Neurol Neurochir Pol; 1981; 15(2):219-22. PubMed ID: 6167888 [No Abstract] [Full Text] [Related]
18. Correlation of the appearance of anti-interferon antibodies during treatment and dimunition of efficacy: summary of an International Workshop on Anti-Interferon Antibodies. Arnason BG; Dianzani F J Interferon Cytokine Res; 1998 Aug; 18(8):639-44. PubMed ID: 9726446 [No Abstract] [Full Text] [Related]
19. The role of interferons in the treatment of multiple sclerosis. Kelley CL J Neurosci Nurs; 1996 Apr; 28(2):114-20. PubMed ID: 8718760 [TBL] [Abstract][Full Text] [Related]
20. Interferon: an early evaluation. McCredie KB; Moore MS J Indiana State Med Assoc; 1980 Sep; 73(9):576-8. PubMed ID: 6158538 [No Abstract] [Full Text] [Related] [Next] [New Search]